Johnson & Johnson received U.S. Food and Drug Administration (FDA) De Novo authorization for its OTTAVA Robotic Surgical System. The system performs various soft tissue procedures, including gastric bypass. This authorization marks the company’s entry into the competitive surgical robotics market.
J&J plans an initial commercial launch with select customers in the United States. The company is currently conducting a U.S. clinical trial for the OTTAVA system in inguinal hernia procedures. J&J will seek regulatory approval in other countries and expand the system's use to additional procedures.
Johnson & Johnson will host an investor conference call on August 3, 2026.